Name: 글로벌 시장 동향
SKU: PH6782
Availability: InStock

보고서 요약(국문)

개요
전 세계 고요산혈증 시장은 2022년 16억 달러 규모에 달했으며, 2023년부터 2030년까지 연평균 5.4%의 성장률을 보이며 2030년에는 34억 달러에 이를 것으로 예상됩니다.
혈액 내 요산 수치가 과도하게 높아지면 고요산혈증이 발생합니다. 고요산혈증은 특별한 증상이 없지만 통풍이나 신장 결석과 같은 질환을 유발할 수 있습니다. 다양한 식품에 함유된 퓨린은 체내에서 분해되어 요산을 생성합니다.
퓨린 함량이 높은 음식과 음료 섭취를 줄이면 혈중 요산 수치를 낮출 수 있습니다. 이렇게 되면 신장이 요산을 더욱 효율적으로 걸러낼 수 있게 됩니다. 남성에 비해 여성의 고요산혈증 유병률은 상당히 낮으며, 50세 미만에서는 1~2%, 50세 이상에서는 약 3% 정도입니다.
또한 최근 연구에 따르면 통풍은 암, 건선, 심방세동, 혈전색전증, 만성폐쇄성폐질환(COPD)과 관련이 있는 것으로 나타났습니다. 심각한 합병증과 삶의 질에 미치는 중대한 영향 때문에 고요산혈증과 통풍은 공중 보건 문제로 대두되었습니다. 급속한 경제 발전과 생활 방식의 변화로 인해 고요산혈증의 유병률이 크게 증가했습니다.
동향
제품 승인 및 임상 시험 증가
고요산혈증의 근본 원인과 통풍과 같은 관련 질환의 분자 메커니즘에 대한 지속적인 연구를 통해 새로운 치료 목표와 접근 방식이 발견되었습니다. 이를 통해 새롭게 개발된 약물과 치료법이 성공을 거둘 수 있게 되었습니다.

예를 들어, 2023년 1월 미국 식품의약국(FDA)은 자이더스 라이프사이언스(Zydus Lifesciences) 사에 페북소스타트(Febuxostat) 40mg 및 80mg 정제의 시판을 최종 승인했습니다. 참조 의약품인 울로릭(Uloric) 정제는 승인된 페북소스타트 40mg 및 80mg 정제와 동일한 효과를 나타냅니다. 페북소스타트 정제는 알로푸리놀 치료에 실패했거나 알로푸리놀 치료를 받을 수 없는 통풍 환자의 고요산혈증(혈중 요산 수치 상승)을 낮추는 데 사용됩니다.
또한, 2023년 6월에는 포트리스 바이오테크(Fortress Biotech, Inc.)의 자회사이자 통풍 및 고요산혈증 관련 질환 치료제 개발 및 상용화에 주력하는 유리카 테라퓨틱스(Urica Therapeutics, Inc.)가 미국에서 건강한 자원자를 대상으로 도티누라드(dotinurad)를 평가한 1상 임상시험의 주요 결과를 발표했습니다. 도티누라드(새로운 요산 운반체)는 모든 용량에서 심각한 부작용이 보고되지 않아 안전하고 내약성이 우수한 것으로 입증되었습니다. 따라서 임상 시험 확대와 제품 승인이 시장 성장을 촉진하고 있습니다.
노령 인구 증가
노령화에 따라 신장 기능이 저하될 수 있습니다. 신장은 체내에서 요산을 여과하고 배설하는 중요한 기능을 합니다. 신장 기능이 저하되면 체내 요산 배설량이 줄어들어 혈중 요산 수치가 상승하고 고요산혈증이 발생할 수 있습니다.
노인들은 식습관과 신체 활동 수준에 변화를 겪을 수 있습니다. 나이가 들면서 과도한 음주나 퓨린이 풍부한 음식 섭취와 같은 건강하지 못한 식습관이 만연하게 됩니다. 이러한 요소들은 노년층의 요산 수치 상승의 원인이 될 수 있습니다.
따라서 노령 인구가 증가함에 따라 시장의 급속한 성장에도 기여하고 있습니다. 예를 들어, 유로스타트에 따르면 2022년 1월 EU 인구는 4억 4,670만 명으로 추산되었으며, 이 중 21.1%가 65세 이상 노인이었습니다. 이는 전년 대비 0.3%포인트, 10년 전 대비 3.1%포인트 증가한 수치입니다.
또한 유엔(UN)의 새로운 보고서에 따르면 전 세계 65세 이상 인구는 향후 30년 동안 두 배로 증가할 것으로 예상됩니다. 2050년에는 노인 인구가 16억 명에 달해 세계 인구의 16% 이상을 차지할 것으로 전망됩니다. 이처럼 노인 인구의 증가는 시장 성장을 견인할 것입니다.
고뇨산혈증 진단에 대한 인식 부족
고뇨산혈증과 관련된 건강 위험은 의료 전문가를 포함한 많은 사람들에게 충분히 인식되지 못하고 있습니다. 이러한 인식 부족은 진단 지연과 부적절한 치료로 이어질 수 있습니다. 또한, 고요산혈증은 특히 통풍이나 기타 관련 질환의 병력이 없는 사람들의 경우 일반적인 건강 검진에서 거의 발견되지 않습니다. 환자들은 정기적인 검사 없이는 자신의 요산 수치가 높아졌다는 사실을 인지하지 못할 수 있습니다. 일부 의료 전문가들은 고요산혈증에 대한 특정 증상이나 위험 요인이 없는 사람들에게는 검사를 우선적으로 고려하지 않을 수 있습니다. 이로 인해 조기 발견 및 교육의 기회를 놓칠 수 있습니다. 따라서 앞서 언급한 요인들이 시장 확장을 저해합니다.
세분화 분석
전 세계 고요산혈증 시장은 유형, 연령대, 약물 유형, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
치료에 필요한 크산틴 산화효소 억제제
크산틴 산화효소 억제제(XO 억제제)라는 약물 계열은 혈중 요산 수치가 높은 질환인 고요산혈증 치료에 사용됩니다. 고요산혈증은 요산 결정 생성을 유발하고, 이 결정이 관절에 축적되어 통증성 염증을 일으키고, 결국 통풍과 같은 질환으로 이어질 수 있습니다.

XO 억제제는 요산 합성에 필수적인 크산틴 산화효소(XO)를 표적으로 작용합니다. 크산틴 산화효소는 요산 전구체인 히포크산틴과 크산틴을 요산으로 전환하는 역할을 합니다. 이 효소가 억제되면 체내 요산 생성이 줄어들어 혈중 총 요산 수치가 낮아집니다. XO 억제제는 이 효소를 차단함으로써 효과를 발휘합니다. XO 억제제는 요산 수치를 낮추고 고요산혈증 및 통풍의 징후와 증상을 치료하는 데 효과적임이 입증되었습니다. XO 억제제는 치료 효과가 입증된, 연구가 많이 진행된 약물입니다. 따라서 이러한 요인들이 시장 확대를 가속화하는 데 도움이 됩니다.
지리적 시장 침투
북미 지역의 질병 유병률
고령화, 비만 증가, 기술 발전, 기업 전략 등의 요인으로 인해 북미 지역은 예측 기간 동안 시장의 대부분을 차지할 것으로 예상됩니다. 예를 들어, 인슐린 저항성은 신체 세포가 혈당 조절을 돕는 호르몬인 인슐린에 반응하지 못하는 질환으로, 비만과 밀접한 관련이 있습니다.
인슐린 저항성으로 인해 혈중 인슐린 수치가 증가하면 신장의 요산 배출 능력이 저하될 수 있으며, 결과적으로 요산 수치가 증가할 수 있습니다. 따라서 비만 증가로 인해 이 분야의 시장 성장이 가속화될 수 있습니다. 예를 들어, 헬스라인 미디어(Healthline Media)에 따르면 미국 성인의 42% 이상이 비만이고 30.7%는 과체중으로 추정됩니다. 과체중 또는 비만은 미국인 전체의 3분의 2 이상에게 영향을 미칩니다.
40~59세 성인이 비만일 가능성이 가장 높으며, 실제로 이 연령대 성인의 44% 이상이 비만입니다. 한편, 60세 이상 성인의 41.5%, 20~39세 성인의 39.8%가 비만입니다. 따라서 이러한 모든 변수들이 해당 지역의 시장 확장을 가속화합니다.
코로나19 영향 분석
코로나19는 고요산혈증과 요산 대사를 모두 악화시킬 수 있습니다. 요산(UA)은 신장 자율 조절을 변화시키고, 내피세포 증식을 억제하며, 세포 사멸을 유도하고, 염증 반응을 촉발하고, 결정 침착을 일으켜 신장에 손상을 줄 수 있습니다. 이번 전염병으로 의료 자원에 부담이 가중되면서 정기 검진과 같은 긴급하지 않은 진료 예약이 연기되거나 지연되었습니다. 이로 인해 고요산혈증 진단 기회를 놓칠 수 있습니다. 일부 사람들은 봉쇄 조치, 제한 사항 및 바이러스 확산에 대한 두려움 때문에 의료 시설 방문을 꺼립니다. 이로 인해 정상적인 의료 치료를 받거나 고요산혈증 검진을 받는 것이 더욱 어려워질 수 있습니다.

유형별
• 1차성
• 2차성
연령대별
• 어린이
• 성인
약물 유형별
• 크산틴 산화효소 억제제
• 비스테로이드성 항염증제
• 코르티코스테로이드
• 기타
투여 경로별
• 경구
• 주사제
유통 채널별
• 병원 약국
• 일반 약국
• 온라인 약국
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
주요 개발 사항
• 2023년 4월, HAMANGO-C 임상시험에서 고요산혈증 및 통풍 치료에 있어 비타민 C의 효능이 검증되었습니다. 미국 미네소타 대학교 연구진은 통풍이 있거나 없는 몽족 사람들의 혈중 요산 수치에 대한 비타민 C 보충의 영향을 확인하기 위해 "몽족 미생물군과 통풍, 비만, 비타민 C(HMANGO-C)" 연구를 시작했습니다.
• 2021년 12월, 임상 단계 바이오테크 기업인 아르트로시 테라퓨틱스(Arthrosi Therapeutics, Inc.)의 신약 후보 물질 AR882의 글로벌 2b상 임상 연구에 환자 등록이 시작되었다고 발표되었습니다. AR882는 만성적이고 난치성인 결절성 통풍 환자의 고요산혈증 치료를 위한 새로운 요산 배설 촉진제로, 현재 임상 연구가 진행 중입니다.

경쟁 환경
시장의 주요 글로벌 업체로는 Arthrosi Therapeutics, Inc., Dr.Reddy's, Urica Therapeutics, Inc., Zydus Lifesciences, Takeda Pharmaceutical Company Limited, Novartis AG, Hikma Pharmaceuticals Plc, Mylan N.V., AstraZeneca Plc, Sun Pharmaceutical Industries Ltd 등이 있습니다.
보고서 구매 이유

• 유형, 연령대, 약물 유형, 투여 경로, 유통 채널 및 지역별 글로벌 고요산혈증 시장 세분화를 시각화하고 주요 상업 자산 및 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴합니다.

• 모든 세그먼트를 포함한 고요산혈증 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 Excel 파일을 제공합니다.

글로벌 고요산혈증 시장 보고서는 약 61개의 표, 58개의 그림, 그리고 186페이지 분량으로 구성됩니다.
주요 대상 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Hyperuricemia Market reached US$ 1.6 billion in 2022 and is expected to reach US$ 3.4 billion by 2030, growing with a CAGR of 5.4 % during the forecast period 2023-2030.
When the bloodstream contains an excessive amount of uric acid, hyperuricemia occurs. Although it doesn't have any symptoms, it can induce diseases like gout or kidney stones. Purine, a substance found in a variety of meals, is broken down by the body to create uric acid as a byproduct.
The amount of uric acid in the blood can be decreased by consuming fewer purine-rich meals and beverages. The kidneys can once again filter uric acid out more efficiently because to this lowering. Compared to men, women have a substantially lower prevalence of hyperuricemia, with 1-2% of those under the age of 50 and about 3% of those over the age of 50.
Moreover, gout has been linked to cancer, psoriasis, atrial fibrillation, thromboembolism, COPD, and thromboembolism, according to recent studies. Due to its serious complications and significant impact on health-related quality of life, hyperuricemia and gout have come to prominence as a public health concern. The prevalence of hyperuricemia has risen significantly as a result of rapid economic development and lifestyle changes.
Dynamics
Increasing the Product Approvals and Clinical trails
Novel objectives and paths for intervention have been found as a result of ongoing study into the underlying causes of hyperuricemia and the molecular mechanisms of related disorders like gout. This makes it possible for newly created medications and treatments to become successful.
For instance, in January 2023, The US Food and Drug Administration (USFDA) gave final approval to Zydus Lifesciences company to market Febuxostat tablets, 40 mg and 80 mg. The reference listed medicine Uloric pills are equivalent to the approved Febuxostat tablets, 40 mg and 80 mg. The purpose of febuxostat tablets is to reduce hyperuricemia (high levels of uric acid in the blood) in gout patients who have either undergone unsuccessful allopurinol treatment or are ineligible for allopurinol therapy.
Additionally, in June 2023, Topline data from the Phase 1 clinical trial evaluating dotinurad in healthy volunteers in the United States has been distributed by Urica Therapeutics, Inc., a Fortress Biotech, Inc. subsidiary company focused on the development and commercialization of pharmaceutical products to treat gout and other conditions associated with hyperuricemia. With no severe adverse effects reported at any dose level, dotinurad (a new urate transporter) was demonstrated to be safe and well tolerated. Thus, the expansion of clinical trials and product approvals fuels the market.
The Increasing Geriatric Population
The function of the kidneys can decrease as ageing population. Filtering and excreting uric acid from the body is a critical function of the kidneys. Reduced kidney function can result in less uric acid being excreted from the body, which causes uric acid levels in the blood to rise and is a sign of hyperuricemia.
Aged persons may encounter changes in their dietary preferences and levels of physical activity. With aging, unhealthy eating patterns like drinking excessive alcohol or purine-rich meals become more prevalent. These elements may be responsible for higher uric acid levels in aged people.
Thus, the aging population is growing, which also contributes to the market's rapid expansion. For instance, according to Eurostat, the EU population in January 2022, was estimated to be 446.7 million, out of which 21.1% were Older individuals aged 65 or over indicating an increase of 0.3 percentage points (pp) to the previous year and an increase of 3.1 pp compared with a decade earlier.
In addition, according to a new report by the United Nations (UN), the number of individuals aged 65 years or above globally is anticipated to increase two folds in the next 30 years. The geriatric population is expected to attain 1.6 billion in 2050, making up over 16% of the world population. By thus increasing the geriatric population will drive the market growth.
Lack of Awareness about Hyperuricemia Diagnosis
The risks to health linked to hyperuricemia may not be fully recognized by many people, including medical experts. This lack of knowledge may result in a delayed diagnosis and poor care. Furthermore, hyperuricemia is rarely detected during standard medical exams, especially in people without a known history of gout or other related disorders. Patients might not be aware of their increased uric acid levels without routine testing. Some medical professionals might not give individuals who don't have certain symptoms or risk factors for hyperuricemia testing priority. Missed chances for early detection and education may come from this. Thus, the previous factors hinder market expansion.
Segment Analysis
The global hyperuricemia market is segmented based on type, age group, drug type, route of administration, distribution channel and region.
Xanthine Oxidase Inhibitors are Needed for Treatment
A class of drugs called Xanthine Oxidase Inhibitors (XO Inhibitors) is used to treat hyperuricemia, a disorder indicated by high amounts of uric acid in the blood. Hyperuricemia can cause uric acid crystals to develop, which can subsequently build up in joints and cause painful inflammation that could eventually result in diseases like gout.
Targeting the xanthine oxidase enzyme, which is essential for the synthesis of uric acid, is how XO inhibitors function. The enzyme xanthine oxidase is in charge of turning the uric acid precursors hypoxanthine and xanthine into uric acid. The body produces less uric acid when this enzyme is inhibited, which lowers the total levels of uric acid in the circulation. XO Inhibitors work by blocking this enzyme. It has been demonstrated that XO inhibitors are efficient at reducing uric acid levels and treating the signs and symptoms of hyperuricemia and gout. They are well-researched drugs with a successful track record in therapeutic use. Thus, these mentioned factors aid in accelerating segment expansion.
Geographical Penetration
Prevalence of the Diseases in the North American Region
Due to factors such as an aging population, an increase in obesity cases, technological improvements, and company strategies, North America is anticipated to hold the majority of the market over the forecast period. For instance, insulin resistance, a disorder in which the body's cells cannot respond to insulin, a hormone that aids in blood sugar regulation, is frequently linked to obesity.
Increased blood insulin levels brought on by insulin resistance may impair the kidneys' capacity to eliminate uric acid. Uric acid levels may increase as a result. As a result, the market may grow faster in the area due to the rise in obesity. For instance, according to healthline media stated that, over 42% of American adults are thought to be obese, while 30.7% are thought to be overweight. Overweight or obese conditions affect more than two thirds of American people overall.
Ages 40 to 59 are when adults are most likely to be obese. In actuality, obesity affects more than 44% of adults in this age range. In the meantime, 41.5% of individuals over the age of 60 and 39.8% of adults between the ages of 20 and 39 are obese. Thus, all of those variables accelerate market expansion in the region.
COVID-19 Impact Analysis
Hyperuricemia and catabolism can both be increased by Covid 19. By altering renal autoregulation, preventing endothelial cells from proliferating, inducing cell death, triggering the pro-inflammatory cascade, and causing crystal deposition, uric acid (UA) has the potential to harm the kidneys. The epidemic has put a burden on healthcare resources, causing non-urgent medical appointments, such as routine check-ups and screenings, to be postponed or delayed. Missed chances to diagnose hyperuricemia could arise from this. Some people avoid going to medical facilities because of lockdowns, limitations, and fear of spreading the virus. This may make it more difficult for them to acquire normal medical treatment or have their hyperuricemia reviewed.
By Type
• Primary
• Secondary
By Age Group
• Children
• Adults
By Drug Type
• Xanthine Oxidase Inhibitors
• Nonsteroidal Anti-Inflammatory Drugs
• Corticosteroids
• Others
By Route of Administration
• Oral
• Injectable
By Distribution Channel
• Hospital pharmacies
• Retail pharmacies
• Online pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In April 2023, in the HAMANGO-C trial, the efficacy of vitamin C in treating hyperuricemia and gout is examined. In order to ascertain the impact of vitamin C supplementation on blood urate levels in Hmong people with or without gout, researchers at the University of Minnesota in the United States have started a study called "the Hmong Microbiome and Gout, Obesity, Vitamin C (HMANGO-C)".
• In December 2021, patient enrollment in a global phase 2b study of AR882, a novel medication candidate from Arthrosi Therapeutics, Inc., a clinical-stage biotech company, was announced. For the treatment of hyperuricemia in gout patients, especially those with chronic, refractory tophaceous gout, AR882 is a novel uricosuric drug now undergoing clinical research.
Competitive Landscape
The major global players in the market include Arthrosi Therapeutics, Inc, Dr.Reddy's, Urica Therapeutics, Inc, Zydus Lifesciences, Takeda Pharmaceutical Company Limited, Novartis AG, Hikma Pharmaceuticals Plc, Mylan N.V., AstraZeneca Plc, Sun Pharmaceutical Industries Ltd and among others.
Why Purchase the Report?
• To visualize the global hyperuricemia market segmentation based on type, age group, drug type, route of adminstration, distribution channel and region,as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of hyperuricemia market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global Hyperuricemia market report would provide approximately 61tables, 58figures and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Age Group
3.3. Snippet by Drug Type
3.4. Snippet by Route of Administration
3.5. Snippet by Distribution Channel
3.6. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing the product approvals and clinical trails
4.1.1.2. The increasing geriatric population
4.2. Restraints
4.2.1.1. Lack of awareness about hyperuricemia diagnosis
4.2.2. Opportunity
4.2.3. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Primary*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Secondary
8. By Age Group
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
8.1.2. Market Attractiveness Index, By Age Group
8.2. Children *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Adults
9. By Drug Type
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.1.2. Market Attractiveness Index, By Drug Type
9.2. Xanthine Oxidase Inhibitors *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Nonsteroidal Anti-Inflammatory Drugs
9.4. Corticosteroids
9.5. Others
10. By Route of Administration
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.1.2. Market Attractiveness Index, By Route of Administration
10.2. Oral*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Injectable
11. By Distribution Channel
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.1.2. Market Attractiveness Index, By Distribution Channel
11.2. Hospital pharmacies*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Retail pharmacies
11.4. Online pharmacies
12. By Region
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.2.8.1. U.S.
12.2.8.2. Canada
12.2.8.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.3.9.1. Germany
12.3.9.2. UK
12.3.9.3. France
12.3.9.4. Italy
12.3.9.5. Spain
12.3.9.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.4.8.1. Brazil
12.4.8.2. Argentina
12.4.8.3. Rest of South America
12.5. Asia-Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.5.8.1. China
12.5.8.2. India
12.5.8.3. Japan
12.5.8.4. Australia
12.5.8.5. Rest of Asia-Pacific
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13. Competitive Landscape
13.1. Competitive Scenario
13.2. Market Positioning/Share Analysis
13.3. Mergers and Acquisitions Analysis
14. Company Profiles
14.1. Arthrosi Therapeutics, Inc*
14.1.1. Company Overview
14.1.2. Product Portfolio and Description
14.1.3. Financial Overview
14.1.4. Key Developments
14.2. Dr.Reddy's
14.3. Urica Therapeutics, Inc
14.4. Zydus Lifesciences
14.5. Takeda Pharmaceutical Company Limited
14.6. Novartis AG
14.7. Hikma Pharmaceuticals Plc
14.8. Mylan N.V.
14.9. AstraZeneca Plc
14.10. Sun Pharmaceutical Industries Ltd
LIST NOT EXHAUSTIVE
15. Appendix
15.1. About Us and Services
15.2. Contact Us

언급된 주요 기업들

Arthrosi Therapeutics, Inc, 4.	Key Developments, Dr.Reddy's, Urica Therapeutics, Inc, Zydus Lifesciences, Takeda Pharmaceutical Company Limited, Novartis AG, Hikma Pharmaceuticals Plc, Mylan N.V., AstraZeneca Plc, Sun Pharmaceutical Industries Ltd

표 목록 (Tables)

List of Tables

Table 1 Global Hyperuricemia Market Value, By Type, 2022, 2026 & 2030 (US$ Billion)

Table 2 Global Hyperuricemia Market Value, By Age Group, 2022, 2026 & 2030 (US$ Billion)

Table 3 Global Hyperuricemia Market Value, By Drug Type, 2022, 2026 & 2030 (US$ Billion)

Table 4 Global Hyperuricemia Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Billion)

Table 5 Global Hyperuricemia Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Billion)

Table 6 Global Hyperuricemia Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 7 Global Hyperuricemia Market Value, By Type, 2022, 2026 & 2030 (US$ Billion)

Table 8 Global Hyperuricemia Market Value, By Type, 2021-2030 (US$ Billion)

Table 9 Global Hyperuricemia Market Value, By Age Group, 2022, 2026 & 2030 (US$ Billion)

Table 10 Global Hyperuricemia Market Value, By Age Group, 2021-2030 (US$ Billion)

Table 11 Global Hyperuricemia Market Value, By Drug Type, 2022, 2026 & 2030 (US$ Billion)

Table 12 Global Hyperuricemia Market Value, By Drug Type, 2021-2030 (US$ Billion)

Table 13 Global Hyperuricemia Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Billion)

Table 14 Global Hyperuricemia Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 15 Global Hyperuricemia Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Billion)

Table 16 Global Hyperuricemia Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 17 Global Hyperuricemia Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 18 Global Hyperuricemia Market Value, By Region, 2021-2030 (US$ Billion)

Table 19 North America Hyperuricemia Market Value, By Type, 2021-2030 (US$ Billion)

Table 20 North America Hyperuricemia Market Value, By Age Group, 2021-2030 (US$ Billion)

Table 21 North America Hyperuricemia Market Value, By Drug Type, 2021-2030 (US$ Billion)

Table 22 North America Hyperuricemia Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 23 North America Hyperuricemia Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 24 North America Hyperuricemia Market Value, By Country, 2021-2030 (US$ Billion)

Table 25 South America Hyperuricemia Market Value, By Type, 2021-2030 (US$ Billion)

Table 26 South America Hyperuricemia Market Value, By Age Group, 2021-2030 (US$ Billion)

Table 27 South America Hyperuricemia Market Value, By Drug Type, 2021-2030 (US$ Billion)

Table 28 South America Hyperuricemia Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 29 South America Hyperuricemia Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 30 South America Hyperuricemia Market Value, By Country, 2021-2030 (US$ Billion)

Table 31 Europe Hyperuricemia Market Value, By Type, 2021-2030 (US$ Billion)

Table 32 Europe Hyperuricemia Market Value, By Age Group, 2021-2030 (US$ Billion)

Table 33 Europe Hyperuricemia Market Value, By Drug Type, 2021-2030 (US$ Billion)

Table 34 Europe Hyperuricemia Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 35 Europe Hyperuricemia Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 36 Europe Hyperuricemia Market Value, By Country, 2021-2030 (US$ Billion)

Table 37 Asia-Pacific Hyperuricemia Market Value, By Type, 2021-2030 (US$ Billion)

Table 38 Asia-Pacific Hyperuricemia Market Value, By Age Group, 2021-2030 (US$ Billion)

Table 39 Asia-Pacific Hyperuricemia Market Value, By Drug Type, 2021-2030 (US$ Billion)

Table 40 Asia-Pacific Hyperuricemia Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 41 Asia-Pacific Hyperuricemia Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 42 Asia-Pacific Hyperuricemia Market Value, By Country, 2021-2030 (US$ Billion)

Table 43 Middle East & Africa Hyperuricemia Market Value, By Type, 2021-2030 (US$ Billion)

Table 44 Middle East & Africa Hyperuricemia Market Value, By Age Group, 2021-2030 (US$ Billion)

Table 45 Middle East & Africa Hyperuricemia Market Value, By Drug Type, 2021-2030 (US$ Billion)

Table 46 Middle East & Africa Hyperuricemia Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 47 Middle East & Africa Hyperuricemia Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 48 Arthrosi Therapeutics, Inc: Overview

Table 49 Arthrosi Therapeutics, Inc: Product Portfolio

Table 50 Arthrosi Therapeutics, Inc: Key Developments

Table 51 Dr.Reddy's: Overview

Table 52 Dr.Reddy's: Product Portfolio

Table 53 Dr.Reddy's: Key Developments

Table 54 Urica Therapeutics, Inc: Overview

Table 55 Urica Therapeutics, Inc: Product Portfolio

Table 56 Urica Therapeutics, Inc: Key Developments

Table 57 Zydus Lifesciences: Overview

Table 58 Zydus Lifesciences: Product Portfolio

Table 59 Zydus Lifesciences: Key Developments

Table 60 Takeda Pharmaceutical Company Limited: Overview

Table 61 Takeda Pharmaceutical Company Limited: Product Portfolio

Table 62 Takeda Pharmaceutical Company Limited: Key Developments

Table 63 Novartis AG: Overview

Table 64 Novartis AG: Product Portfolio

Table 65 Novartis AG: Key Developments

Table 66 Hikma Pharmaceuticals Plc: Overview

Table 67 Hikma Pharmaceuticals Plc: Product Portfolio

Table 68 Hikma Pharmaceuticals Plc: Key Developments

Table 69 Mylan N.V.: Overview

Table 70 Mylan N.V.: Product Portfolio

Table 71 Mylan N.V.: Key Developments

Table 72 AstraZeneca Plc: Overview

Table 73 AstraZeneca Plc: Product Portfolio

Table 74 AstraZeneca Plc: Key Developments

Table 75 Sun Pharmaceutical Industries Ltd: Overview

Table 76 Sun Pharmaceutical Industries Ltd: Product Portfolio

Table 77 Sun Pharmaceutical Industries Ltd: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Hyperuricemia Market Value, 2021-2030 (US$ Billion)

Figure 2 Global Hyperuricemia Market Share, By Type, 2022 & 2030 (%)

Figure 3 Global Hyperuricemia Market Share, By Age Group, 2022 & 2030 (%)

Figure 4 Global Hyperuricemia Market Share, By Drug Type, 2022 & 2030 (%)

Figure 5 Global Hyperuricemia Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 6 Global Hyperuricemia Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 7 Global Hyperuricemia Market Share, By Region, 2022 & 2030 (%)

Figure 8 Global Hyperuricemia Market Y-o-Y Growth, By Type, 2022-2030 (%)

Figure 9 Primary Hyperuricemia Market Value, 2021-2030 (US$ Billion)

Figure 10 Secondary Hyperuricemia Market Value, 2021-2030 (US$ Billion)

Figure 11 Global Hyperuricemia Market Y-o-Y Growth, By Age Group, 2022-2030 (%)

Figure 12 Children Age Group in Global Hyperuricemia Market Value, 2021-2030 (US$ Billion)

Figure 13 Adults Age Group in Global Hyperuricemia Market Value, 2021-2030 (US$ Billion)

Figure 14 Global Hyperuricemia Market Y-o-Y Growth, By Drug Type, 2022-2030 (%)

Figure 15 Xanthine Oxidase Inhibitors Drug Type in Global Hyperuricemia Market Value, 2021-2030 (US$ Billion)

Figure 16 Nonsteroidal Anti-Inflammatory Drugs Drug Type in Global Hyperuricemia Market Value, 2021-2030 (US$ Billion)

Figure 17 Corticosteroids Drug Type in Global Hyperuricemia Market Value, 2021-2030 (US$ Billion)

Figure 18 Others Drug Type in Global Hyperuricemia Market Value, 2021-2030 (US$ Billion)

Figure 19 Global Hyperuricemia Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 20 Oral Route of Administration in Global Hyperuricemia Market Value, 2021-2030 (US$ Billion)

Figure 21 Injectable Route of Administration in Global Hyperuricemia Market Value, 2021-2030 (US$ Billion)

Figure 22 Global Hyperuricemia Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 23 Hospital pharmacies Distribution Channel in Global Hyperuricemia Market Value, 2021-2030 (US$ Billion)

Figure 24 Retail pharmacies Distribution Channel in Global Hyperuricemia Market Value, 2021-2030 (US$ Billion)

Figure 25 Online pharmacies Distribution Channel in Global Hyperuricemia Market Value, 2021-2030 (US$ Billion)

Figure 26 Global Hyperuricemia Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 27 North America Hyperuricemia Market Value, 2021-2030 (US$ Billion)

Figure 28 Asia-Pacific Hyperuricemia Market Value, 2021-2030 (US$ Billion)

Figure 29 Europe Hyperuricemia Market Value, 2021-2030 (US$ Billion)

Figure 30 South America Hyperuricemia Market Value, 2021-2030 (US$ Billion)

Figure 31 Middle East and Africa Hyperuricemia Market Value, 2021-2030 (US$ Billion)

Figure 32 North America Hyperuricemia Market Value, 2021-2030 (US$ Billion)

Figure 33 North America Hyperuricemia Market Share, By Type, 2022 & 2030 (%)

Figure 34 North America Hyperuricemia Market Share, By Age Group, 2022 & 2030 (%)

Figure 35 North America Hyperuricemia Market Share, By Drug Type, 2022 & 2030 (%)

Figure 36 North America Hyperuricemia Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 37 North America Hyperuricemia Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 38 North America Hyperuricemia Market Share, By Country, 2022 & 2030 (%)

Figure 39 South America Hyperuricemia Market Value, 2021-2030 (US$ Billion)

Figure 40 South America Hyperuricemia Market Share, By Type, 2022 & 2030 (%)

Figure 41 South America Hyperuricemia Market Share, By Age Group, 2022 & 2030 (%)

Figure 42 South America Hyperuricemia Market Share, By Drug Type, 2022 & 2030 (%)

Figure 43 South America Hyperuricemia Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 44 South America Hyperuricemia Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 45 South America Hyperuricemia Market Share, By Country, 2022 & 2030 (%)

Figure 46 Europe Hyperuricemia Market Value, 2021-2030 (US$ Billion)

Figure 47 Europe Hyperuricemia Market Share, By Type, 2022 & 2030 (%)

Figure 48 Europe Hyperuricemia Market Share, By Age Group, 2022 & 2030 (%)

Figure 49 Europe Hyperuricemia Market Share, By Drug Type, 2022 & 2030 (%)

Figure 50 Europe Hyperuricemia Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 51 Europe Hyperuricemia Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 52 Europe Hyperuricemia Market Share, By Country, 2022 & 2030 (%)

Figure 53 Asia-Pacific Hyperuricemia Market Value, 2021-2030 (US$ Billion)

Figure 54 Asia-Pacific Hyperuricemia Market Share, By Type, 2022 & 2030 (%)

Figure 55 Asia-Pacific Hyperuricemia Market Share, By Age Group, 2022 & 2030 (%)

Figure 56 Asia-Pacific Hyperuricemia Market Share, By Drug Type, 2022 & 2030 (%)

Figure 57 Asia-Pacific Hyperuricemia Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 58 Asia-Pacific Hyperuricemia Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 59 Asia-Pacific Hyperuricemia Market Share, By Country, 2022 & 2030 (%)

Figure 60 Middle East & Africa Hyperuricemia Market Value, 2021-2030 (US$ Billion)

Figure 61 Middle East & Africa Hyperuricemia Market Share, By Type, 2022 & 2030 (%)

Figure 62 Middle East & Africa Hyperuricemia Market Share, By Age Group, 2022 & 2030 (%)

Figure 63 Middle East & Africa Hyperuricemia Market Share, By Drug Type, 2022 & 2030 (%)

Figure 64 Middle East & Africa Hyperuricemia Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 65 Middle East & Africa Hyperuricemia Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 66 Arthrosi Therapeutics, Inc: Financials

Figure 67 Dr.Reddy's: Financials

Figure 68 Urica Therapeutics, Inc: Financials

Figure 69 Zydus Lifesciences: Financials

Figure 70 Takeda Pharmaceutical Company Limited: Financials

Figure 71 Novartis AG: Financials

Figure 72 Hikma Pharmaceuticals Plc: Financials

Figure 73 Mylan N.V.: Financials

Figure 74 AstraZeneca Plc: Financials

Figure 75 Sun Pharmaceutical Industries Ltd: Financials

세계 고요산혈증 시장 – 2023-2030

Global Hyperuricemia Market - 2023-2030